This systematic review and meta-analysis evaluated the efficacy and safety of cannabinoids for various medical conditions. The study included 79 randomized controlled trials (RCTs) involving 6,462 participants. The main outcomes assessed were patient-relevant/disease-specific outcomes, activities of daily living, quality of life, global impression of change, and adverse events (AEs). Cannabinoids showed some benefit for chronic pain and spasticity, with moderate-quality evidence supporting their use. For nausea and vomiting due to chemotherapy, weight gain in HIV, sleep disorders, and Tourette syndrome, there was low-quality evidence of improvement. However, these associations did not reach statistical significance in all trials. Cannabinoids were associated with an increased risk of short-term AEs, including serious AEs. Common AEs included dizziness, dry mouth, nausea, fatigue, somnolence, euphoria, vomiting, disorientation, drowsiness, confusion, loss of balance, and hallucination. The study found that cannabinoids were associated with improvements in chronic pain and spasticity, but these effects were not consistently significant. For nausea and vomiting due to chemotherapy, weight gain in HIV, sleep disorders, and Tourette syndrome, there was some evidence of improvement, though not statistically significant in all cases. Cannabinoids were associated with an increased risk of short-term AEs, including serious AEs. Common AEs included dizziness, dry mouth, nausea, fatigue, somnolence, euphoria, vomiting, disorientation, drowsiness, confusion, loss of balance, and hallucination. The study concluded that there was moderate-quality evidence to support the use of cannabinoids for the treatment of chronic pain and spasticity. There was low-quality evidence suggesting that cannabinoids were associated with improvements in nausea and vomiting due to chemotherapy, weight gain in HIV, sleep disorders, and Tourette syndrome. Cannabinoids were associated with an increased risk of short-term AEs.This systematic review and meta-analysis evaluated the efficacy and safety of cannabinoids for various medical conditions. The study included 79 randomized controlled trials (RCTs) involving 6,462 participants. The main outcomes assessed were patient-relevant/disease-specific outcomes, activities of daily living, quality of life, global impression of change, and adverse events (AEs). Cannabinoids showed some benefit for chronic pain and spasticity, with moderate-quality evidence supporting their use. For nausea and vomiting due to chemotherapy, weight gain in HIV, sleep disorders, and Tourette syndrome, there was low-quality evidence of improvement. However, these associations did not reach statistical significance in all trials. Cannabinoids were associated with an increased risk of short-term AEs, including serious AEs. Common AEs included dizziness, dry mouth, nausea, fatigue, somnolence, euphoria, vomiting, disorientation, drowsiness, confusion, loss of balance, and hallucination. The study found that cannabinoids were associated with improvements in chronic pain and spasticity, but these effects were not consistently significant. For nausea and vomiting due to chemotherapy, weight gain in HIV, sleep disorders, and Tourette syndrome, there was some evidence of improvement, though not statistically significant in all cases. Cannabinoids were associated with an increased risk of short-term AEs, including serious AEs. Common AEs included dizziness, dry mouth, nausea, fatigue, somnolence, euphoria, vomiting, disorientation, drowsiness, confusion, loss of balance, and hallucination. The study concluded that there was moderate-quality evidence to support the use of cannabinoids for the treatment of chronic pain and spasticity. There was low-quality evidence suggesting that cannabinoids were associated with improvements in nausea and vomiting due to chemotherapy, weight gain in HIV, sleep disorders, and Tourette syndrome. Cannabinoids were associated with an increased risk of short-term AEs.